

FDA Advisory Committee Briefing Document

Prepared by the Division of Reproductive and Urologic Products
Office of Drug Evaluation III
December 21, 2006

General Meeting on Contraceptives

Bibliography

Introduction

1. Clinical Trial Design

- 1.1 Guideline on Clinical Investigation of Steroid Contraceptives in Women. EMEA, Adopted in July 2005.
- 1.2 Draft Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA, February 2006.
- 1.3 Helmerhorst FM et al. The Cochrane Fertility Regulation Group: synthesizing the best evidence about family planning. Contraception 2006 Oct; 74(4): 280-6.

2. Contraceptive Efficacy and Risk-Benefit Assessment

- 2.1 Trussell J. Contraceptive failure in the United States. Contraception 2004 Aug; 70(2): 89-96.
- 2.2 Gallo MF et al. Twenty micrograms vs. >20 microgram estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005 Mar; 71(3): 162-9.
- 2.3 Gerlinger C et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003 Jun; 8(2): 87-92.

3. Cycle Control (Unscheduled Bleeding and Spotting)

- 3.1 Mishell DR et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007 Jan 75(1) 4-10.
- 3.2 Mishell DR et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007 Jan; 75(1): 11-5.

4. **Translation of Clinical Trial Findings into the “Real World”**

- 4.1 Moos M-K et al. Counseling in the clinical setting to prevent unintended pregnancy: an evidence-based research agenda. Contraception 2003 Feb; 67(2): 115-32.
- 4.2 Rosenberg MJ et al. Compliance and oral contraceptives: A review. Contraception 1995; 52: 137-41.
- 4.3 Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J Pediatr Adolesc Gynecol 2001, 14: 153-62.

5. **Extended Dosing Regimens**

- 5.1 Edelman A et al. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006 Mar; 21(3): 573-8.
- 5.2 Birch RL et al. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 2006 Mar; 73(3): 235-43.

6. **Phase 4 Commitments**

- 6.1 Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiology Assessment. FDA, March 2005.
- 6.1 Sidney S et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004, 70: 3-10.
- 6.3 Skegg DC. Evaluating the safety of medicines, with particular reference to contraception. Stat Med 2001; 20(23):3557-3569.
- 6.4 Burkman RT et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001 Aug; 185(2 Suppl): S4-12.

7. **Role and Impact of Labeling**

- 7.1 Draft Guidance for Industry - Labeling for Human Prescription Drug and Biological Products- Implementing the New Content and Format Requirements. FDA, January 2006.
- 7.2 Steiner MJ et al. Communicating contraceptive effectiveness: A randomized controlled trial to inform a World Health Organization family planning handbook. Am J Obstet Gynecol 2006 Jul; 195(1): 85-91.
- 7.3 Curtis KM et al. Effective use of hormonal contraceptives, Part I: Combined oral contraceptive pills. Contraception 2006 Feb; 73(2): 115-24.